Quick filters

111 trials match your criteria

Muscular dystrophy

Not recruiting

Study on the Effects of Ribitol (BBP-418) in Patients with Limb Girdle Muscular Dystrophy Type 2I

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years

Study on the Effects of Pariglasgene Brecaparvovec for Adults with Glycogen Storage Disease Type Ia

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years

Study on the Effects and Safety of RO7204239 for Patients with Facioscapulohumeral Muscular Dystrophy

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years

Study on the Safety and Efficacy of Viltolarsen for Boys with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years

Congenital myopathy

Not recruiting

Study on Salbutamol for Improving Muscle Strength in Patients with Congenital Myopathy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years

Study on the Long-Term Safety and Effectiveness of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years

Study to Determine the Best Dose of Vesleteplirsen for Patients with Duchenne Muscular Dystrophy Suitable for Exon 51-Skipping Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years

Study of Pariglasgene Brecaparvovec and Prednisolone for Adults with Glycogen Storage Disease Type Ia

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years

Study on the Safety and Effects of mRNA-3745 for Patients with Glycogen Storage Disease Type 1a (GSD1a)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years

Study on the Safety and Effects of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years

powered byClinicalTrials.eu